Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline

International Journal of Neuropsychopharmacology

Volumn 6, Issue 4, 2003, Pages 339-346

  Joyce, Peter R ^a   Mulder, Roger T ^a   Luty, Suzanne E ^a   McKenzie, Janice M ^a   Miller, Allison L ^a   Rogers, Geraldine R ^a   Kennedy, Martin A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antidepressants; G protein 3 subunit; Pharmacogenomics; Serotonin transporter

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; FLUOXETINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA3 SUBUNIT; NORTRIPTYLINE; PROTEIN SUBUNIT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADOLESCENCE; ADULT; AGE; ALLELE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HOPKINS SYMPTOM CHECKLIST; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL STATE EXAMINATION FOR MELANCHOLIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOMES RESEARCH; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; SCORING SYSTEM; SELF REPORT; SEROTONIN TRANSPORTER GENE; SOCIAL ADJUSTMENT SCALE; STRUCTURED CLINICAL INTERVIEW FOR DSM III R SCALE; TEMPERAMENT AND CHARACTER INVENTORY;

ADULT; AGE FACTORS; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIPOLAR DISORDER; CARRIER PROTEINS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; GENOTYPE; GTP-BINDING PROTEIN BETA SUBUNITS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NORTRIPTYLINE; PERSONALITY ASSESSMENT; PERSONALITY INVENTORY; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 0742305531     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003663     Document Type: Article

References (36)

1. Alda M (2001). Genetic factors and treatment of mood disorders. Bipolar Disorders 3, 318-324.
2. Anderson IM (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19-36.
3. Arranz MJ, Collier D, Kerwin RW (2001). Pharmacogenetics for the individualization of psychiatric treatment. American Journal of Pharmacogenetics 1, 3-10.
4. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, Allilaire JF, Feingold J, Mallet J, Malafosse A (1998). Association between the tryptophan hydroxylase gene and manic-depressive illness. Archives of General Psychiatry 55, 33-37.
5. Ciulla TA, Sklar RM, Hauser SL (1988). A simple method for DNA purification from peripheral blood. Analytical Biochemistry 174, 485-488.
6. Cloninger CR, Svrakic DM, Przybeck TR (1993). A psychobiological model of temperament and character. Archives of General Psychiatry 50, 975-990.
7. Derogatis L (1983). SCL-90-R Administration, Scoring and Procedures Manual. Baltimore, MD.
8. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL (1998). Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depression and Anxiety 7, 32-39.
9. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes, CW, Carmody T, Rintelmann J (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 54, 1031-1037.
10. Farfel Z, Bourne HR, Iiri T (1999). The expanding spectrum of G protein diseases. New England Journal of Medicine 340, 1012-1020.
11. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
12. Hamm HE (1998). The many faces of G protein signaling. Journal of Biological Chemistry 273, 669-672.
13. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D (1995). Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. British Medical JournaI 310, 897-901.
14. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP (1996). Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry 66, 2621-2624.
15. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Abbott RM, Stevens IF (2002a). Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response. Australian and New Zealand Journal of Psychiatry 36, 376-383.
16. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF (2002b). Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Australian and Nezo Zealand Journal of Psychiatry 36, 384-391.
17. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ (2000). Serotonin transporter gene polymorphism and antidepressant response. NeuroReport 11, 215-219.
18. Kwok S, Kellogg DE (1990). Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Research 18, 999-1005.
19. Luty SE, Joyce PR, Mulder RT, McKenzie JM (2002). Social adjustment in depression: the impact of depression severity, personality, and clinic versus community sampling. Journal of Affective Disorders 70, 143-154.
20. Montgomery SA, Asberg MA (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
21. Mulder RT, Watkins WGA, Joyce PR, Luty SE (2003). Serotonergic antidepressants are superior to noradrenergic antidepressants in depressed young adults. Journal of Affective Disorders 76, 143-149.
22. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF (1989). Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Research 17, 2503-2516.
23. Parker G, Hadzi-Pavlovic D (1996). Melancholia A Disorder of Movement and Mood. New York: Cambridge University Press.
24. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587-590.
25. Serretti A, Lilli R, Smeraldi E (2002). Pharmacogenetics in affective disorders. European Journal of Pharmacology 438, 117-128.
26. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E (2001). Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular Psychiatry 6, 586-592.
27. Siffert W (2000). G protein beta3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy. Nephrology Dialysis Transplantation 15, 1298-1306.
28. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B (1998). Association of a human G-protein beta3 subunit variant with hypertension, Nature Genetics 18, 45-48.
29. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 3, 508-511.
30. Spitzer RL, Williams JB, Gibbon M, First MB (1992). The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Archives of General Psychiatry 49, 624-629.
31. Steffens DC, Krishnan KR, Helms MJ (1997). Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depression and Anxiety 6, 10-18.
32. Steimer W, Muller B, Leucht S, Kissling W (2001). Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clinica Chimica Acta 308, 33-41.
33. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2001). C825T Polymorphism of the G protein Beta3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37, 739-743.
34. Weissman MM, Bothwell S (1976). Assessment of social adjustment by patient self-report. Archives of General Psychiatry 33, 1111-1115.
35. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of Clinical Psychopharmacology 20, 105-107.
36. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B (2000). Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. NeuroReport 11, 1893-1897.